Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Case Report

Volumetric Modulated Arc Radiotherapy Efficacy after Double Recurrences of Cardiac Sarcoma

Author(s): Antonio Rosario Pisani, Angela Sardaro, Nicola Maggialetti, Corinna Altini*, Dino Rubini, Paolo Mammucci and Giuseppe Rubini

Volume 20, 2024

Published on: 25 May, 2023

Article ID: e100423215583 Pages: 6

DOI: 10.2174/1573405620666230410091236

open_access

Abstract

Background: Volumetric Modulated Arc Therapy (VMAT) has recently become a pivotal treatment of oncological diseases due to the high-precise delineation of target volume contours with sparing organs at risk. This procedure requires a high level of experience and precision and is achievable only with advanced diagnostic support. Magnetic Resonance (MRI) and multimodality imaging, such as 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), are fundamental in implementing radiotherapy guidance.

Case Report: A 54-year-old patient underwent surgery twice to remove primitive and recurrent cardiac sarcomas of the left atrium. The appearance of a further relapse required radiotherapy as the only possible treatment. Cardiac MRI was then performed to define the degree of atrial mass invasiveness, and 18F-FDG PET/CT was performed to assess the activity and staging of the cardiac lesion. It revealed high 18F-FDG uptake not only in the left atrium lesion but also in a pancreatic lesion with elevated 18F-FDG uptake (SUV max 5.5). The pancreatic biopsy performed a few days later confirmed the myxoid sarcoma metastasis, and surgeons defined it as not operable due to the patient’s clinical condition. Radiotherapy was then urgently performed with the VMAT technique. After 40 days, a cardiac MRI showed a reduction in the cardiac mass with improvement in the respiratory and cardiac symptoms; then, the patient started chemotherapy. One year after diagnosis, the patient is still alive and is receiving chemotherapy with gemcitabine and docetaxel with good compliance.

Conclusion: The correct and timely management of a patient suffering from a rare oncological disease has allowed a better and longer survival, especially due to VMAT, a sophisticated procedure that requires high expertise. This case also demonstrates that cardiac MRI and whole-body imaging procedures, such as 18FDG PET/CT, can be useful in staging patients with oncological diseases.

Keywords: VMAT, Cardiac sarcoma, Therapy strategies, MRI, 18F-FDG PET/CT, Case report.

[1]
Patel J, Sheppard MN. Pathological study of primary cardiac and pericardial tumours in a specialist UK Centre: surgical and autopsy series. Cardiovasc Pathol 2010; 19(6): 343-52.
[http://dx.doi.org/10.1016/j.carpath.2009.07.005] [PMID: 19747857]
[2]
Moeri-Schimmel R, Pras E, Desar I, Krol S, Braam P. Primary sarcoma of the heart: Case report and literature review. J Cardiothorac Surg 2020; 15(1): 104.
[http://dx.doi.org/10.1186/s13019-020-01157-4] [PMID: 32430055]
[3]
Ferrari C, Nappi AG, Santo G, et al. The day after mass covid-19 vaccination: Higher hypermetabolic lymphadenopathy detection on PET/CT and impact on oncologic patients management. Cancers (Basel) 2021; 13(17): 4340.
[http://dx.doi.org/10.3390/cancers13174340] [PMID: 34503150]
[4]
Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010; 144(1): 3-15.
[http://dx.doi.org/10.1016/j.ijcard.2010.03.003] [PMID: 20399520]
[5]
Koutroumpakis E, Palaskas NL, Lin SH, et al. Modern radiotherapy and risk of cardiotoxicity. Chemotherapy 2020; 65(3-4): 65-76.
[http://dx.doi.org/10.1159/000510573] [PMID: 33049738]
[6]
Bakaeen FG, Reardon MJ, Coselli JS, et al. Surgical outcome in 85 patients with primary cardiac tumors. Am J Surg 2003; 186(6): 641-7.
[http://dx.doi.org/10.1016/j.amjsurg.2003.08.004] [PMID: 14672772]
[7]
Isambert N, Ray-Coquard I, Italiano A, et al. Primary cardiac sarcomas: A retrospective study of the French Sarcoma Group. Eur J Cancer 2014; 50(1): 128-36.
[http://dx.doi.org/10.1016/j.ejca.2013.09.012] [PMID: 24135684]
[8]
Andrushchuk U, Ostrovsky Y, Zharkov V, et al. Surgery for massive malignant tumors of the left atrium – one center’s experience. Kardiochir Torakochirurgia Pol 2016; 3(3): 229-35.
[http://dx.doi.org/10.5114/kitp.2016.62610] [PMID: 27785137]
[9]
Plana JC. Added value of real-time three-dimensional echocardiography in assessing cardiac masses. Curr Cardiol Rep 2009; 11(3): 205-9.
[http://dx.doi.org/10.1007/s11886-009-0029-5] [PMID: 19379640]
[10]
Scicchitano P, Sergi MC, Cameli M, et al. Primary soft tissue sarcoma of the heart: An emerging chapter in cardio-oncology. Biomedicines 2021; 9(7): 774.
[http://dx.doi.org/10.3390/biomedicines9070774] [PMID: 34356838]
[11]
Araoz PA, Eklund HE, Welch TJ, Breen JF. CT and MR imaging of primary cardiac malignancies. Radiographics 1999; 19(6): 1421-34.
[http://dx.doi.org/10.1148/radiographics.19.6.g99no031421] [PMID: 10555666]
[12]
Maleszewski JJ, Anavekar NS, Moynihan TJ, Klarich KW. Pathology, imaging, and treatment of cardiac tumours. Nat Rev Cardiol 2017; 14(9): 536-49.
[http://dx.doi.org/10.1038/nrcardio.2017.47] [PMID: 28436488]
[13]
Sparrow PJ, Kurian JB, Jones TR, Sivananthan MU. MR imaging of cardiac tumors. Radiographics 2005; 25(5): 1255-76.
[http://dx.doi.org/10.1148/rg.255045721] [PMID: 16160110]
[14]
Altini C, Niccoli Asabella A, Lavelli V, et al. Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer. Recenti Prog Med 2019; 110(3): 144-50.
[PMID: 30968855]
[15]
Rahbar K, Seifarth H, Schäfers M, et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med 2012; 53(6): 856-63.
[http://dx.doi.org/10.2967/jnumed.111.095364] [PMID: 22577239]
[16]
The role of PET/CT in radiation treatment planning for cancer patient treatment. IAEA-TECDOC-1603 2008.
[17]
Sardaro A, Turi B, Bardoscia L, Ferrari C, Rubini G, Calabrese A. The role of multiparametric magnetic resonance in volumetric modulated arc radiation therapy planning for prostate cancer recurrence after radical prostatectomy: A pilot study. Front Oncol 2021; 10: 603994.
[http://dx.doi.org/10.3389/fonc.2020.603994]

© 2024 Bentham Science Publishers | Privacy Policy